Webappendix: Supplementary figures and tables for "Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials" *Analyses are by allocated treatment: tamoxifen vs control (no adjuvant tam.)*

Page 1	Webapp	oendix c	ontents (Click on any i	tem to ju	Imp direc	tly to	it)		
2 3 4	10-year risks, recurrence & breast cancer mortality, RRs for recurrence, multiple subgroup analyses, RRs for death with recurrence,							: 1, 2 or ~5 y : ~5 years ta "	/ears tam. am.	
5	15-year	risks, 4	outcome	s, age at entry	/ < 45 y	ears,	ER+	: ~5 years ta	am.	
6				"	45-54 y	ears,				
7					55-69 y	ears,				
8	10-year	risks,		"	70+ y	ears,	"	н		
9	15-year	contrala	ateral bre	ast cancer inc	idence,	all ages	, by	ER status:	~5 years ta	m.
10						by age	,	ER+ only:		
11	15-year	uterus o	cancer in	cidence & mo	rtality,	all ages	, ER	+ & all ER:		
12			" in	cidence,		by age	,	ER+ only:		
13						by age	,	all ER:		
14	15-year	stroke /	PE / othe	er vascular mo	ortality,	all ages	,	ER+ only:		
15	"		"	"	"	all ages	,	all ER:	"	
16 17	Table of "	f deaths	by cause "	e & second ca "	ncers,		I	ER+ only: all ER:	~5 years ta "	m.
18-35	Forest p	olots, on	e line / tr	ial, by ER and	tam. du	ration (1,	2 or	~5 years)		
18	RRs for	recurre	nce in ye	ars 0-4, one li	ne / trial	, È	R+: 1	, 2 or ~5 ye	ars tam.	
19	RRs for	recurre	nce in ye	ars 5-9,	н	-				
20	RRs for	recurre	nce in ye	ars 10+,						
21	RRs for	death w	ith recur	rence,						
22	RRs for	death w	vithout re	currence,						
23	RRs for	any dea	ath,							
24-29	RRs in s	same 5 f	orest plo	ts as pp 18-23	8,	but ER-po	oor:			
30-35	RRs in s	same 5 f	orest plo	ts as pp 18-23	, but E	R-unknov	wn:	н		
36	Referen	ices and	names o	of the trials of	~5 years	s tam. vs o	ontr	ol		

p 2: 10-year recurrence & breast cancer mortality, ER+ disease: 1, 2 or 5 years tam.



p 3: RRs for recurrence, multiple subgroup analyses, ER+ disease: ~5 years tam.

Category	Events/wor Allocated tamoxifen	man-years Allocated control	Tamoxif Logrank O-E	fen event Variance of O-E	s e <u>Ratio of annu</u> Tamoxifen	al event rates : Control
(a) Dose (trend γ^2 =	5·4; 2p = 0).02)				
<u>(1) 20 mg/d</u> (1 cm 2,1	1134/40962 (2·8%/y)	1547/36557 (4·2%/y)	′− 273·8	627·6		0·65 (se 0·03)
30 mg/d	250/5710	313/4199	-76·6	118·4		0.52 (SE 0.07)
40 mg/d	(4·4%/y) 269/10075 (2·7%/y)	(7·5%/y) 358/8120 (4·4%/y)	-83·1	135.4	-=-	0·54 (se 0·06)
(b) Background che	emotherap	$\chi(\chi_1^2 = 7.7$; 2p = (D·006)		
Present	837/22900 (3·7%/y)	1057/20528 (5·1%/y)	8−170·5	430·1		0·67 (se 0·04)
Absent	816/33847 (2·4%/y)	1161/28348 (4·1%/y)	8−263·1	451·3		0·56 (se 0·04)
(c) Background che	emotherap	$\chi(\chi_1^2 = 2.1)$; 2p = 0)·1; NS)	1	
Concurrent	352/7096	433/5817	-81·8	169·2		0.62 (SE 0.06)
Sequential	(5·0%/y) 485/15804	(7·4%/y) 624/14711	-88.7	260.0	T_	0.71 (SE 0.05)
ocquentiai	(3·1%/y)	(4·2%/y)	007	200 3		0 / 1 (32 0 00)
Absent	816/33847 (2·4%/y)	1161/28348 (4·1%/y)	8-263.1	451·3		0·56 (se 0·04)
(d) Entry age (trend	l χ <mark>²</mark> = 5·5; 2	p = 0·02)			I.	
Age < 45	406/11846	572/10690	-105.1	226.9	_ 	0·63 (SE 0·05)
45 - 54	(3·4 %/y) 494/16768	(5 [.] 4%/y) 615/15678	-83.8	256.8	T-	0·72 (se 0·05)
FF C0	(2·9%/y)	(3·9%/y)	000.0	074.0		0.54 (0= 0.04)
55 - 69	(2·7%/y)	963/21215 (4·5%/y)	-228.8	374.9	F	0.24 (SE 0.04)
70+	41/1512 (2·7%/v)	68/1293 (5:3%/y)	−15·8	22.8	•	0·50 (se 0·15)
Age unknown	0/11	0/0			I	
(e) Nodal status (tre	(0.0%/y) and $v^2 = 0.2$	$2 \cdot 2n = 0.7$	· NS)			
	752/27672	1105/22174	-227.6	442.2	<u>_</u>	0.60 (cr. 0.04)
N0/N=	(2·0%/y)	(3·3%/y)	-79.8	443 [.] 3		0.64 (SE 0.04)
NAL	(3·4%/y)	(5·3%/y)	02.2	101.0		0.56 (05.0.06)
N4T	(7·0%/y)	432/3776 (11·4%/y)	-93.2	161.3		0.20 (SE 0.06)
Other / unknown	197/3852 (5·1%/y)	236/3462 (6·8%/y)	-33.0	96.7		0·71 (SE 0·09)
(f) Tumour differen	tiation (χ_1^2 =	= 1·1; 2p =	0·3; N	S)	I	
Poorly-diff.	101/2022	170/1730	-38.5	58·1	- - -	0·52 (se 0·10)
Moderately/Well	(5·0%/y) 201/4285	(9·8%/y) 251/3513	-48.8	99·3	_ #	0·61 (se 0·08)
Grade unknown	(4·7%/y) 1351/50461 (2·7%/y)	(7·1%/y) 1797/43645	5 − 333·2	734·9		0·64 (se 0·03)
	(Z ⁻¹ /0/y)	(4°176/y)				
(g) Tumour diamete	er (trend χ_1^2	= 1·2; 2p	= 0·3; I	NS)	1	
1 – 20 mm (T1)	647/29188 (2·2%/y)	905/25511 (3·5%/y)	− 188·2	365.8		0.60 (se 0.04)
21 – 50 mm (T2)	771/20603 (3·7%/y)	1000/17847 (5·6%/y)	7−169∙0	403·5	-	0.66 (se 0.04)
> 50 mm (T3/T4)	78/1462	110/1337	− 17·2	36.9		0.63 (SE 0.13)
Other / unknown	(5·3 %/y) 157/5495	(8·2 %/y) 203/4173	-40.5	78·8		0.60 (SE 0.09)
(h) Site of first recu	(2.9%) rrence (γ^2	(4 ^{·9} %/y) = 2·1: p =	0·4: NS	5)	I	
Isolated local	205/34320	317/29618	-74.6	121.7		0.54 (SE 0.07)
Contralateral	(0.6%/y)	(1·1%/y)	-65.1	136.8	- <u>+</u>	0.62 (SE 0.07)
Distant/Multiple	(0·4%/y) 1098/54960	(0·7%/y) 1417/47560)-262·4	558.8		0.63 (SE 0.03)
Unknown	(2·0%/y) 113/56714	(3·0%/y) 157/48827	-31.4	64·1		0·61 (se 0·10)
(i) Time since rend	(U·2%/y)	(0·3%/y) trond ~ ² -	43.7.4	2n < 0.0	0001)	
	240/40000		475 A	-h - n.n	— 1	0.47 (0- 0.05)
rears 0 - 1 2 - 4	343/10229 (3·4%/y) 548/13434	676/9825 (6·9%/y) 790/11894	-175·3	230·2		0.47 (SE 0.05)
	(4·1%/y)	(6·6%/y)	100.0	557 3	1	
5 - 9	454/17258 (2·6%/y)	499/14372 (3·5%/y)	-82·5	217.6	┦╋┻╌╴	0.68 (SE 0.06)
10+	308/15631 (2·0%/y)	253/12610 (2·0%/y)	-7.7	128.8	— •	0·94 (se 0·09)
Total	1653/ 56747 (2∙9%/y)	2218/ 48876 (4∙5%/y)	-433·5	881·4	ł	0·611 (SE 0·027) 2p < 0·00001
-∎- 99% or <⊥> 95% cor	fidence intervals				0.5 1	0 1.5
Global I	neterogeneity	/: χ ² ₁₀ = 69·0	; p < 0·0	0001	Tamoxifen better	Tamoxifen worse

Treatment effect 2p < 0.00001

p 4: RRs for death with recurrence, multiple subgroup analyses, ER+ disease: ~5 years tam.

Category	Deaths/ Allocated tamoxifen	Women Allocated control	Tamoxi Logran O−E	fen death k Varianc of O-E	e Ratio of annua Tamoxifen :	<u>l death rates</u> Control
(a) Dose (trend χ^2_4 =	2·8; 2p = 0	0.09)				
20 mg/d	758/3919 (19·3%)	, 997/3917 (25·5%)	−125·2	415·2	-	0·74 (se 0·04)
30 mg/d	190/651	245/624	- 52·8	96·2		0·58 (se 0·08)
40 mg/d	(29·2%) 212/779	(39·3%) 292/755	-46·5	108·8		0.65 (SE 0.08)
	(27.2%)	(38·7%)			-	
(b) Background che	emotherapy	$y(\chi_1^2 = 2.2)$	2; 2p =	0·1; NS)		
Present	566/2719 (20·8%)	685/2715 (25·2%)	-86.2	289.2	-##	0·74 (se 0·05)
Absent	594/2630 (22·6%)	849/2581 (32·9%)	− 138·3	331·0	-	0·66 (SE 0·04)
(c) Background che	emotherapy	$\chi(\chi_1^2 = 1.1)$; 2p =	0·3; NS)		
Concurrent	257/984	298/989	-45·4	122·7	_ #	0.69 (se 0.08)
Sequential	(26·1%) 309/1735	(30·1%) 387/1726	-40.8	166·4		0·78 (se 0·07)
Absent	(17·8%) 594/2630	(22·4%) 849/2581	-138·3	331·0		0.66 (se 0.04)
	(22.6%)	(32.9%)			Ľ-∦Γ	, , , , , , , , , , , , , , , , , , ,
(d) Entry age (trend	I χ ² ₁ = 2·4; 2	p = 0·1; N	IS)		I	
Age < 45	277/1297 (21·4%)	378/1317 (28·7%)	-53.8	156.6	_ #	0·71 (se 0·07)
45 - 54	316/1665	365/1690	− 31·4	158·8		0·82 (SE 0·07)
55 - 69	(19 ^{.0} %) 529/2240	728/2133	− 130·3	284.8		0.63 (se 0.05)
70+	(23·6%) 38/146	(34·1%) 63/156	-9.0	10.0		0.64 (SE 0.18)
	(26·0%)	(40·4%)	50	19.9	_	
Age unknown	(0.0%)	0/0				
(e) Nodal status (tre	and $\chi_1^2 = 0.0$); 2p = 0·8	8; NS)		I	
N0/N-	491/2975 (16·5%)	737/2975 (24·8%)	− 112·9	293.9		0.68 (SE 0.05)
N1-3	247/1119 (22·1%)	311/1092 (28·5%)	− 39·1	127.9	— — —	0·74 (se 0·08)
N4+	281/716	330/681 (48·5%)	− 56·1	131.8	_∎_	0.65 (SE 0.07)
Other / unknown	141/539 (26·2%)	(156/548 (28·5%)	-16.4	66.6		- 0·78 (se 0·11)
(f) Tumour different	tiation (χ_1^2 =	= 0·1; 2p =	= 0·8; N	S)	1	
Poorly-diff.	79/295	117/323	-14·3	43.6		0·72 (SE 0·13)
Moderately/Well	130/611	159/591	-24.4	64·8	_	0·69 (se 0·10)
Grade unknown	(21 [.] 3%) 951/4443	(20·9%) 1258/4382	-174·3	519·2		0·71 (se 0·04)
	(21.4%)	(28.7%)			T	
(g) Tumour diamete	er (trend χ_1^2	= 1·1; 2p	= 0·3;	NS)		
1 – 20 mm (T1)	404/2478 (16·3%)	580/2425 (23·9%)	-97·7	233.0		0.66 (SE 0.05)
21 – 50 mm (T2)	571/2134 (26·8%)	725/2162 (33·5%)	-81·9	302.6		0·76 (se 0·05)
> 50 mm (T3/T4)	58/193	82/202	− 13·1	28.4	_	0·63 (se 0·15)
Other / unknown	(30·1%) 127/544	(40 [.] 6%) 147/507	-14·1	60·1		0.79 (se 0.11)
(h) Time since rand	(23·3%)	(29.0%) (trend χ_1^2	= 0.0; 2	2p = 0·9	; NS)	
Years 0 - 1	92/5349	127/5296	− 18·9	50·9	#	0·69 (se 0·12)
2 - 4	(1·7%) 358/5142	(2·4%) 478/5048	-65.5	193·9		0·71 (se 0·06)
5 - 9	(7·0%) 433/4553	(9·5%) 580/4358	-95.8	233.2		0.66 (SF 0.05)
10+	(9.5%)	(13·3%)		140.0		0.73 (or 0.07)
-	277/3156 (8·8%)	349/2857 (12·2%)	-44.3	142.0		U'/3 (SE U'U/)
Denominators: wo	men entering	time period			I	0.000 / 0.000
Total	5349 (21·7%)	5296 (29·0%)	-224.5	620·2	Ŷ	0·696 (SE 0·034) 2p < 0·00001
🖶 99% or <-> 95% cor	nfidence intervals			_	0.5 1.0	1.5
Global I	neterogeneitv	/: χ ² = 9·7; ι	o = 0·3		Tamoxifen better	Tamoxifen worse
		~8 - · · ·			Treatment effect	t 2p < 0·00001









p 9: 15-year contralateral breast cancer incidence, all ages, by ER status: ~5 years tam.













p 15: 15-year stroke, PE & other/all vascular mortality, all ER: ~5 years tam.



p 16: Table 1: Mortality by cause and incidence of second cancers, ER+ disease. Outcome by allocated treatment in trials of about 5 years of adjuvant tamoxifen. (Webappendix p 17 gives results for all women, irrespective of ER status.)

	Events	(O-E)	Variance	Rate Ratio & SE	2p*
Death without recurrence	1117	4.9	258.6	1.02 0.06	0.79
Death with recurrence	2694	-224.5	620.2	0.70 0.03	< 0.00001
Any death	3811	-219-6	878-8	0.78 0.03	< 0.00001
Death without recurrence (se Vascular disease:	lected gro	oups of caus	es)		
Stroke	64	4.8	15-2	1.37 0.30	0.27
Pulmonary embolus†	12	2.5	3.0	2.30 0.90	0.25
Heart & other vascular	212	-6-1	50-1	0.89 0.13	0.43
Neoplastic disease:					
Uterus excluding cervix‡	10	3.2	2.2	4.28 1.52	0.07
Other non-breast	187	-0-1	44-2	1.00 0.15	1.00
Other specified cause	312	4.6	71.0	1.07 0.12	0.63
Unknown cause (but definitely not-breast cancer**)	320	-4.0	72.9	0.95 0.11	0.68
Second cancer incidence with Contralateral breast, by age at entry (years)	hout previ	ious recurre	nce (selected sit	es)	
< 45	110	-17.7	27.2	0.52 0.14	0.001
45 - 54	169	-18.8	41.5	0.64 0.12	0.004
55 - 69	268	-28.7	64.0	0.64 0.10	0.00001
≥70	17	0.1	4.1		-
All ages	564	-65-1	136.7	0.62 0.07	< 0.00001
Uterus excluding cervix,‡ by age at entry (years)					
< 45	11	0.1	2.7	1.04 0.62	1.00
45 - 54	25	3.3	5.9	1.75 0.55	0.25
55 - 69	71	18.0	16.6	2.96 0.44	0.00002
≥70	1	0.8	0.2		-
All ages	108	22.2	25.4	2.40 0.32	0.00002
Other or unknown site	606	2.6	143.6	1.02 0.08	0.86

* 2p, with continuity correction

† 6 vs 0 deaths from pulmonary embolus during years 0-4 (all with entry age 55-69 years) and 3 vs 3 later (all with entry age 55+ years).

‡ 9 vs 1 deaths (age at entry: 45-54 years, 1 vs 0; 55-69 years, 7 vs 1; 70+ years, 1 vs 0) and 83 vs 25 incident cases of uterine cancer, excluding cervix

** Deaths from an unknown cause that might possibly have been breast cancer were taken to have been immediately preceded by recurrence.

p 17: Table 2: Mortality by cause and incidence of second cancers, all ER. Outcome by allocated treatment in trials of about 5 years of adjuvant tamoxifen.

	Events	(O-E)	Variance	Rate Ratio & SE	2p*
Death without recurrence	1805	25.0	410.0	1.06 0.05	0.23
Death with recurrence	4789	-265.6	1074.5	0.78 0.03	< 0.00001
Any death	6594	-240-5	1484.5	0.85 0.02	< 0.00001
Death without recurrence (se Vascular disease:	elected gro	oups of caus	es)		
Stroke	107	11.3	24.5	1.59 0.26	0.03
Pulmonary embolus†	23	3.0	5.4	1.74 0.58	0.28
Heart & other vascular	319	-12-8	74.8	0.84 0.11	0.16
Neoplastic disease:					
Uterus excluding cervix‡	19	7.3	4.3	5.46 1.27	0.001
Other non-breast	324	2.4	76.5	1.03 0.11	0.41
Other specified cause	470	5.6	103.6	1.06 0.10	0.62
Unknown cause (but definitely not-breast cancer**)	543	8.2	120.9	1.07 0.09	0.60
Second cancer incidence with Contralateral breast,	thout prev	vious recurre	nce (selected si	tes)	
All ages	940	-77.2	223.6	0.71 0.06	< 0.00001
Uterus excluding cervix,‡ by age at entry (years)					
< 45	21	-0-8	5.2	0.86 0.41	0.90
45 - 54	45	3.3	5.9	1.75 0.55	0.02
55 - 69	110	30.2	25.9	3.21 0.37	< 0.00001
≥70	6	1.6	1.1		-
All ages	182	39.3	42.9	2.50 0.25	< 0.00001
Other or unknown site	1026	-0.8	241.7	1.00 0.06	0.98

* 2p, with continuity correction

† 9 vs 2 deaths from pulmonary embolus during years 0-4 (age at entry: < 45 years 0 vs 1, 45-54 years 1 vs 0, 55-69 years 8 vs 1) and 7 vs 5 later (age at entry: < 45 1 vs 0, 55-69 5 vs 4, 70+ 1 vs 1).

‡ 18 vs 1 deaths (age at entry: 45-54 years, 4 vs 0; 55-69 years, 13 vs 1; 70+ years, 1 vs 0) and 137 vs 45 incident cases of uterine cancer, excluding cervix

** Deaths from an unknown cause that might possibly have been breast cancer were taken to have been immediately preceded by recurrence.

p 18: RRs for recurrence in years 0-4, one line / trial, ER+ disease: by tam. duration



p 19: RRs for recurrence in years 5-9, one line / trial, ER+ disease: by tam. duration



* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/woman-years.

p 20: RRs for recurrence in years 10+, one line / trial, ER+ disease: by tam. duration



and in final total of events/woman-years.

p 21: RRs for death with recurrence, one line / trial, ER+ disease: by tam. duration



p 22: RRs for death without recurrence, one line / trial, ER+ disease: by tam. duration



and in final total of deaths/woman-years.

p 23: RRs for any death, one line / trial, ER+ disease: by tam. duration



and in final total of deaths/women.

p 24: RRs for recurrence in years 0-4, one line / trial, ER-poor disease: by tam. duration



* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/woman-years.

p 25: RRs for recurrence in years 5-9, one line / trial, ER-poor disease: by tam. duration



and in final total of events/woman-years.

[†] Tamoxifen plus chemotherapy versus same chemotherapy alone

p 26: RRs for recurrence in years 10+, one line / trial, ER-poor disease: by tam. duration

	Tamovifon	Events/wo	man-years	Tamoxif	en events			
Year code and study name	dose (mg/d) & duration (y)	Allocated tamoxifen	Adjusted control	Logrank O-E	Variance of O-E	<u>Ratio of ann</u> Tamoxifen	ual event rates : Control	
(a) Tamoxifen for	average of ab	out 1 yea	r					
74G2 Case Western A 77C Danish BCG 77c 78A2 S Sweden II:1	†40 1 30 1 30 1	3/104 2/133 0/79	0/44 0/103 0/121	1∙0 0∙4	0·6 0·2 –			>
78H Innsbruck 20 1 78M NCCTG/Mayo Clinic †20 1		0/0 9/460	0/3 3/393	2.7	2.7			>
78V ECOG 5177/6177 79B1 SWOG 7827 A	7 †20 1 †20 1	11/474 1/52	5/409 1/19	1.8	3.5		-	>
82B1 DBCG 82b preme	+ 20 1 enop.† 30 1 + 20 1	1/182	0/200 2/128	-0.8	0.2 – 0.5 –			>
85J123578 PetrovStPetersb'	g †20 1	3/54	2/34	0.8	0.5		•	\rightarrow
∎ (a) subtotal		32/ 1762 (1∙8%/y)	13/ 1519 (0∙9%/y)	6·4	8-8		2·07 (inc 2p	SE 0·49) rease = 0·03
(b) Tamoxifen for	average of 2 y	/ears						
72J Copenhagen	30 2	0/420	1/257	-0.6	0·2			>
76G1458 Stockholm B 77H NATO	†40 2 20 2	5/297 6/586	2/228 3/331	1·2 0·3	1·2 1·7			\rightarrow
77K NSABP B-09 78B1 Toronto-Edmont.	. <u>120</u> 2 . <u>30</u> 2	3/66	1/28	-0·4 -0·1	0.4 0.6 -			\rightarrow
78U GON Naples 78J ECOG EST1178 78S12345 NKCC Japan	20 2	0/1 3/210	0/123 0/4 4/259	-1.0	1.4			~~~~
79D1+2 GABG/HD Germa	any †30 2 30 2	0/224	1/195	-0·5	0·3	G-		\rightarrow
80P GABG 2 German	y 30 2 +40 2	0/11	0/31 1/17	00	02			
81A Montpellier France 81B IB Bordeaux	ce 30 2 +30 2	0/11 1/12	0/18 1/6					
82L1246 ACETBC-1 82R1+3 Amsterdam C820	†202 9*301 or 3	0/101 2/77	0/98 2(1/57)	0.1	0.5 –			>
83F1+2 Oita 84A1+5 GBSG 02 Germa	†20 2 ny †30 2	0/2 0/14	0/7 0/37					
84Q4 Austrian BCSG 4 84U SE Sweden BCG	20 2 20 /40 2	0/0 1/28	0/1 3/36	-1·2	0·5 —			>
87A1+2 ZIPP * 90L Stockholm 7	†20 2 40 2	10/207 2/164	2(2/112) 4/163	1·4 −0·9	2·0 1·5			> >
■ (b) subtotal		51/ 3423 (1∙5%/y)	41/ 2990 (1∙4%/y)	0∙1	16-6		1·01 (SE 0·25) rease
(c) Tamoxifen for	average of 3 c	or more (n	nedian: 5)	vears			2p >	0·1; NS
76Core-th Stockholm P	+40. 2 or 5	12/002	17/1207	-2.5	6.1			
78D1234 Scottish 78F CRFB Caen C5 82%1 NSABP B-14	20 5 or 10+ 40 3 20 5 or 10	9/514 2/20 0/24	3/404 0/16 0/23	0·5 0·3	1·9 0·2 —	_		>
82M Osaka 83B GROCTA I Italy	†20 5 †30 5	0/14 0/0	0/27 0/11					
86M2 CRFB Caen 002 86P2 FASG GFEA 02	30 5 †30 3	2/23 0/61	0/12 2/47	0·5 -0·4	0·3 - 0·2			\longrightarrow
89B2 SWOG 8897 89F ECOG EST5188	†20 5 †20 5	2/81	21/1641 1/112	-3·5 0·6	8.0 0.7	B		>
91H NSABP B-23	†20 5 †20 5	8/588	8/587 _/8	-0·1	4·0			>
93B NCIC MA.12 93N IBCSG 13-93	†20 5 †20 5 †20 5	2/34 0/10	0/24 0/9	1.0	0·5			>
■ (c) subtotal		51/	53/	-4.1	22.7		0·84 (se 0·19)
_ (,,		3909 (1∙3%/y)	4132 (1·3%/y)				redi 2p >	uction 0·1; NS
■ Total (a + b +	c)	134/ 9094 (1·5%/y)	107/ 8641 (1·2%/y)	2.2	48·1	_	1-053 (inc 2p >	SE 0·148) rease 0·1; NS
	95% confidence etween 3 subt	te intervals otals: χ_c^2 =	s = 5·3; p = 1	0·07	0	0.5	1.0 1.5	2.0
Heterogenei	ity within subt	otals: χ^2_{2}	= 31·7; p	> 0·1;	NS	Tamoxifen better	Tamoxifen w	orse
Heterogeneit	y between 31	trials: χ^2_{20}	= 37·0; p	> 0·1;	NS	Treatment effect 2	p > 0·1; NS, advo	erse
		- 30			Tre	end between 3 subt	otals: χ ₁ ² = 4·6; 2	p = 0·03
* For balan	ce, control patie	ents in 3-	way trials of	or trial s	strata co	unt half or twice in s	ubtotal(s)	

and in final total of events/woman-years.

p 27: RRs for death with recurrence, one line / trial, ER-poor disease: by tam. duration



* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

p 28: RRs for death without recurrence, one line / trial, ER-poor disease: by tam. duration







* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

p 30: RRs for recurrence in years 0-4, one line / trial, ER-unknown disease: by tam. duration



For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/woman-years.

p 31: RRs for recurrence in years 5-9, one line / trial, ER-unknown disease: by tam. duration



* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/woman-years.

p 32: RRs for recurrence in years 10+, one line / trial, ER-unknown disease: by tam. duration

and etudy name	dose (mg/d)	Allocated	Adjusted	Logrank	Variance	Ratio of annu	al event rates
(a) Tamoxifen for	r average of ab	out 1 vea	control	0-6	01 U-E	ramoxiten	
<u>(u) rumoxnon ioi</u>	urorugo or us	<u>out i jou</u>					
76F2 Christie B 77C Danish BCG 77c	20 1	9/981 26/1537	28/752 28/1256	-9·9 -2·6	8·4 12·4		
7F3467 UK MCCG 009	†20 0.5	0/1	1/87	20		-	
78A2 S Sweden II:1	30 1	6/393 5/150	11/442	-1·8	3·6		\rightarrow
82B1 DBCG 82b prem	10 120 1 1enop.†30 1	3/469	8/545	-2.2	2.7		^
82L3+5 ACETBC-1	†20 1	3/62	2/63	0.3	1.0		>
84S1 Kawasaki 2	†20 1	5/470	5/454	(no	data) 2.1	_	
Kawasaki 1	?? 1	5/4/5	5/454	(no	data)		
		57/	94/				0 00 /0- 0 44
(a) subtotal v	vith data §	4072	3724	-14.9	31.1		reduction
(h) Taur anifau fa		(1·4%/y)	(Z·3%/Y)				2p = 0·008
(b) Tamoxiten to	r average of 2	/ears					
72J Copenhagen	30 2	1/26	0/0	0.3	0.2 -		>
76G1458 Stockholm B 77H NATO	T40 2 20 2	8/448 15/887	7/901	-0·3 3·0	2·0 4·7	•	\rightarrow
77K NSABP B-09	+20 2	11/550	8/399	1.5	4.1		>
78B1 Toronto-Edmon	t. 30 2	4/124	4/39	-1.5	1.5 -		>
78C GUN Naples 78F LIK/Asia Collab	T30 2 +40 2	2/81	2/96	-0·1 -1·0	0·4 – 2·8		>
78J ECOG EST1178	3 20 2	2/26	0/10	10	20	-	-
BS12345 NKCC Japan	†20 2	0/10	0/64				
78Y1 Ghent Univ.	20 2	0/75	0/40	2.4	3.8		
80D1 CRC2, UK	†20 2	36/2808	37/2548	-3.1	16.8		
80E Toulouse France	e 30 2	1/139	5/166	-1.4	1.0 -	•	>
80S1 Helsinki	†40 2 20 2	0/9	0/0	0.5	1.6		
82\$ ACETBC-1	+20 2	4/143	3/125	(no	data)		· · · · · · · · · · · · · · · · · · ·
32L1246 ACETBC-1	†20 2	0/33	1/32		,		
82N Kumamoto	†20 2	4/100	2(0/22)	(no	data)		
83F1+2 Oita	+20 2	4/108	2(0/32)	0.7	0.3		
84A1+5 GBSG 02 Germa	any †30 2	0/2	0/1				
84U SE Sweden BCC	3 20 /40 2	1/28	2/55	-0.2	0.1 -	•	>
86F1 Osaka BCSG Ja	T30 2 anan 40 2			(no (no	data) data)		
86K Wisconsin U.	20 2	0/0	0/1	(uulu)		
87A1+2 ZIPP *	†20 2	6/196	2(0/63)	1.3	0.9		>
87E1 Oita	†20 2 22 22			(no	data)		
88W6+7 ACETRC-3	+ 20 / 30 2			(no (no	data) data)		
89H CSGBCT Japan	20 2			(no	data)		
91J GBSG V German	ny 302			(no	data)		
92C ACETBC-4 ??C2 LMU Munich Ge	†202 rmany ?? ??			(no (no	data) data)		
■ (b) subtotal v	with data §	119/	94/	2∙0	40·6	_	1·05 (se 0·16
		6724 (1·8%/y)	5992 (1·6%/y)				increase 2p > 0·1; NS
(c) Tamovifon for		or more (n	nedian: 5	1 100			
	r average or 3 c			years			
6G239ab Stockholm B	†40 2 or 5	10/695	6/562	years 2·1	3.5		>
G239ab Stockholm B 8D1234 Scottish	†40 2 or 5 20 5 or 10+	10/695 26/1105	6/562 17/966	2·1	3·5 8·9		
G239ab Stockholm B 8D1234 Scottish 78F CRFB Caen C5 80H2 Marceille	+40 2 or 5 20 5 or 10+ 40 3 +30 3	10/695 26/1105 2/59	6/562 17/966 3/50	2·1 0·0 -0·6	3·5 8·9 0·2 — data)		• • • • • • • • • • • • • • • • • • •
G239ab Stockholm B 8D1234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka	+40 2 or 5 20 5 or 10+ 40 3 †30 3 †20 5	10/695 26/1105 2/59 0/27	6/562 17/966 3/50 0/40	2·1 0·0 -0·6 (no	3·5 8·9 0·2 — data)		• • • • • • • • • • • • • • • • • • •
G239ab Stockholm B 8D1234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002	+40 2 or 5 20 5 or 10+ 40 3 +30 3 +20 5 30 5	10/695 26/1105 2/59 0/27 6/392	6/562 17/966 3/50 0/40 7/506	2·1 0·0 -0·6 (no 0·2	3.5 8.9 0.2 — data) 2.8	- <u></u>	• • • • • • • • • • • • • • • • • • •
G239ab Stockholm B 8D1234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 86P2 FASG GFEA 02 80/20 Part Indu	+40 2 or 5 20 5 or 10+ 40 3 +30 3 +20 5 30 5 +30 3 20 5	10/695 26/1105 2/59 0/27 6/392 1/43	6/562 17/966 3/50 0/40 7/506 0/48	2·1 0·0 -0·6 (no 0·2 0·5	3.5 8.9 0.2 — data) 2.8 0.3 -	- <u></u>	· · · · · · · · · · · · · · · · · · ·
G239ab Stockholm B 8D1234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 86P2 FASG GFEA 02 89@2 Bari Italy 89B2 SWOG 8897	+40 2 or 5 20 5 or 10+ 40 3 +20 5 20 5 30 5 +30 3 20 5 +30 3 20 5 +20 5	10/695 26/1105 2/59 0/27 6/392 1/43 0/110	6/562 17/966 3/50 0/40 7/506 0/48 1/98	2·1 0·0 -0·6 (no 0·2 0·5 (no	3·5 8·9 0·2 — data) 2·8 0·3 - data)	·	• • • • • • • • • • • • • • • • • • •
G239ab Stockholm B 8D1234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 86P2 FASG GFEA 02 89@2 Bari Italy 89B2 SWOG 8897 89L NSABP B-21	+40 2 or 5 20 5 or 10+ 40 3 +30 3 +20 5 30 5 +30 3 +20 5 20 5 +30 3 20 5 +30 3 20 5	10/695 26/1105 2/59 0/27 6/392 1/43 0/110 8/375	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389	2·1 0·0 -0·6 (no 0·2 0·5 (no -0·2	3.5 8.9 0.2 — data) 2.8 0.3 - data) 3.8		
G239ab Stockholm B 801234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 86P2 FASG GFEA 02 89@2 Bari Italy 89B2 SWOG 8897 89L NSABP B-21 91C EORTC 10901	+40 2 or 5 20 5 or 10+ 40 3 +30 3 +20 5 30 5 +30 3 20 5 +20 5 20 5 +20 5 20 5 +20 5 20 5 +20 5 20 5	10/695 26/1105 2/59 0/27 6/392 1/43 0/110 8/375 0/15	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389 0/4	2·1 0·0 -0·6 (no 0·2 0·5 (no -0·2	3.5 8.9 0.2 — data) 2.8 0.3 - data) 3.8		· · · · · · · · · · · · · · · · · · ·
G239ab Stockholm B 801234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 86P2 FASG GFEA 02 89B2 Bari Italy 89B2 SWOG 8897 89L NSABP B-21 91C EORTC 10901 92N1 ICCG C/9/91 UK P1/243 BASO II	+40 2 or 5 20 5 or 10+ 40 3 +30 3 +20 5 30 5 +30 3 +20 5 20 5 +20 5	10/695 26/1105 2/59 0/27 6/392 1/43 0/110 8/375 0/15 -/6 3/48	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389 0/4 -/7 4/108	2.1 0.0 -0.6 (<i>no</i> 0.2 0.5 (<i>no</i> -0.2	3.5 8.9 0.2 — data) 2.8 0.3 - data) 3.8 1.5		
G239ab Stockholm B 801234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 86P2 FASG GFEA 02 89B2 SWOG 8897 89L SABP B-21 91C EORTC 10901 92N1 ICCG C9/91 UK P1+2+3 BASO II 33C5+6 GABG 4 German	+40 2 or 5 20 5 or 10+ 40 3 +30 3 +20 5 20 5 +30 3 +20 5 20 5 +20 5 +20 5 20 5 +20 5 20 5 +20 3 1 20 +20 5 20 5 20 5 1 20 20 5 20 5 20 5 1 20 20 5 1 20 20 5 1 30	10/695 26/1105 2/59 0/27 6/392 1/43 0/110 8/375 0/15 -/6 3/48	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389 0/4 -/7 4/108	2.1 0.0 -0.6 (no 0.2 0.5 (no -0.2 0.3 (no	3.5 8.9 0.2		· · · · · · · · · · · · · · · · · · ·
(C) removine (O) (G239ab Stockholm B 8D1224 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 80P2 FASG GFEA 02 89@2 Bari Italy 89B2 SWOG 8897 89L NSABP B-21 91C EORTC 10901 92N1 ICCG C/9/91 UK (P1+2+3 BASO II 33C5+6 GABG 4 German 93N IBCSG 13-93 98X GEPARDO Gerr	+40 2 or 5 20 5 or 10+ 40 3 +20 5 20 5 20 5 20 5 20 5 20 5 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 120 5 120 5 120 5 120 5 120 5 120 5 120 5 120 5 120 5 120 5	10/695 26/1105 2/59 0/27 6/392 1/43 0/110 8/375 0/15 -/6 3/48 0/0	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389 0/4 -/7 4/108 0/2	2.1 0.0 −0.6 (<i>no</i> 0.2 0.5 (<i>no</i> −0.2 0.3 (<i>no</i> (<i>no</i>)	3.5 8.9 0.2 data) 2.8 0.3 - data) 3.8 1.5 data) data)	·	
G239ab Stockholm B 8D1234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 86P2 FASG GFEA 02 80@2 Bari Italy 89@2 Bari Italy 89B2 SWOG 8897 89L NSABP B-21 91C EORTC 10901 92N1 ICCG C/9/91 UK P1+2+3 BASO II 93C5+6 GABG 4 German 93N IBCSG 13-93 98X GEPARDO Gerr	two rage of 3 f +40 2 or 5 20 5 or 10+ 40 3 +20 5 :30 3 +20 5 :40 3 :40 3 :40 3 :40 3 :20 5 :20 5 :20 5 :20 5 :20 5 :20 5 :20 5 :20 5 :20 5 :20 5 :20 5 :20 5 :20 5 :20 5 :100 5 :100 5 :100 5 :100 5	10/695 26/1105 2/59 0/27 6/392 1/43 0/110 8/375 0/15 -/6 3/48 0/0 56/	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389 0/4 -/7 4/108 0/2 4/6/	2:1 0:0 -0:6 (<i>no</i> 0:2 0:5 (<i>no</i> -0:2 0:3 (<i>no</i> (<i>no</i> 0:3	3.5 8.9 0.2 data) 2.8 0.3 - data) 3.8 1.5 data) data) data)		
GC239ab Stockholm B '8D1234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 86P2 FASG GFEA 02 80@2 Bari Italy 89B2 SWOG 8897 89L NSABP B-21 91C EORTC 10901 92N1 ICCG C/9/91 UK 2P1+2+3 BASO II 93N IBCSG 13-93 98X GEPARDO Gerr (C) subtotal v	+40 2 or 5 20 5 or 10+ 40 3 +20 5 :30 5 :40 3 :20 5 <td:20< td=""> 5</td:20<>	10/695 26/1105 2/59 0/27 6/392 1/43 0/110 8/375 0/15 -/6 3/48 0/0 56/ 2875 (1-9%/y)	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389 0/4 -/7 4/108 0/2 46/ 2780 (1.7%/y)	2:1 0:0 -0:6 (no 0:2 0:5 (no -0:2 0:3 (no (no 2:3	3.5 8.9 0.2 data) 2.8 2.8 data) 3.8 1.5 data) data) data) 20.9		1.12 (SE 0.2: increase 2p > 0.1; NS
G239ab Stockholm B 8D1234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 89@2 Bari Italy 89@2 Bari Italy 89@2 Bari Italy 99@2 Bari Italy 92N1 CCG C/9/91 UK 92N1 ICCG C/9/91 UK 221+2+3 BASO II 93N IBCSG 13-93 98X GEPARDO Gerr (c) subtotal v	+40 2 or 5 20 5 or 10+ 40 3 +20 5 20 5 130 3 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 120 5 many +30 vith data §	10/695 26/1105 2/59 0/27 6/392 1/43 0/110 8/375 0/15 -/6 3/48 0/0 56/ 2875 (1.9%/y) 232/ 13671 (1.7%/y)	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389 0/4 -/7 4/108 0/2 46/ 2780 (1.7%/y) 224/ 12496 (1.8%/y)	2:1 0:0 -0:6 (<i>no</i> 0:2 0:5 (<i>no</i> -0:2 0:3 (<i>no</i> 2:3 -10:5	3.5 8.9 0.2 – data) 2.8 0.3 – data) 3.8 1.5 data) data) 20.9 92.6		1.12 (SE 0.23 increase 2p > 0.1; NS 0.893 (SE 0.05 reduction 2p > 0.1; NS
G239ab Stockholm B 8D1234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 86P2 FASG GFEA 02 89@2 Bari Italy 89B2 SWOG 8897 89L NSABP B-21 91C EORTC 10901 92N1 ICCG C/9/91 UK P1-2+3 BASO II 93C5+6 GABG 4 German 93N IBCSG 13-93 98X GEPARDO Gerr • (c) subtotal v • Total (a + b +	+40 2 or 5 20 5 or 10+ 40 3 +20 5 30 3 +20 5 with data § • c) 95% confidence	10/695 26/1105 2/59 0/27 6/392 1/43 0/110 8/375 0/15 -/6 3/48 0/0 56/ 2875 (1-9%/y) 232/ 13671 (1-7%/y) 22 (1-10) 232/ 13671 (1-7%/y)	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389 0/4 -/7 4/108 0/2 46/ 2780 (1.7%/y) 224/ 12496 (1.8%/y)	2:1 0:0 -0:6 (no 0:2 0:5 (no -0:2 0:3 (no (no 2:3 -10:5	3.5 8.9 0.2 data) 2.8 0.3 - data) 3.8 1.5 data) data) 20.9 92.6		1.12 (SE 0.23 increase 2p > 0.1; NS 0.893 (SE 0.05 reduction 2p > 0.1; NS
G239ab Stockholm B 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 86P2 FASG GFEA 02 89@2 Bari Italy 93@2 Bari Italy 93P2 FASG GFEA 02 89@2 Bari Italy 93P2 FASG GFEA 02 89@2 Bari Italy 93P2 FASG GFEA 02 89@2 Bari Italy 93P2 FASG GFEA 02 93@2 Bari Italy 93P2 FASG GFEA 02 93P2 FASG GFEA 02 93P2 FASG GFEA 02 93P2 FASG GFEA 02 93P3 FASG FEA	+40 2 or 5 20 5 or 10+ 40 3 +20 5 20 5 130 3 +20 5 +30 3 20 5 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 nany +30 vith data § • • c) • 95% confidence vetween 3 subt	$\begin{array}{c} 10/695\\ 26/1105\\ 2/59\\ 0/27\\ 6/392\\ 1/43\\ 0/110\\ 8/375\\ 0/15\\ -/6\\ 3/48\\ 0/0\\ \hline \\ 56/\\ 2875\\ (1.9\%/y)\\ \hline \\ 232/\\ 13671\\ (1.7\%/y)\\ \approx intervals\\ otals: \chi^2_2 = 0$	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389 0/4 -/7 4/108 0/2 46/ 2780 (1-7%/y) 224/ 12496 (1-8%/y) : 6-3; p =	2:1 0:0 -0:6 (<i>no</i> 0:2 0:5 (<i>no</i> -0:2 0:3 (<i>no</i> 2:3 -10:5	3.5 8.9 0.2 – data) 2.8 2.8 3.8 1.5 data) 20.9 92.6	0.5 1	1.12 (SE 0.23 increase 2p > 0.1; NS 0.893 (SE 0.05 reduction 2p > 0.1; NS 0 1.5 2.0 Tamoxifen worse
G239ab Stockholm B '8D1234 Scottish 78F CRFB Caen C5 80H2 Marseille 82M Osaka 86M2 CRFB Caen 002 89@2 FASG GFEA 02 89@2 Bari Italy 89B2 SWOG 8897 89L NSABP B-21 91C EORTC 10901 92N1 ICCG C/9/91 UK 2914:243 BASO II 93C546 GABG 4 German 93N IBCSG 13-93 98X GEPARDO Gerr ■ (c) subtotal v ■ Total (a + b + = 99% or ← Heterogeneity E Heterogeneity E	+40 2 or 5 20 5 or 10+ 40 3 +20 5 or 10+ 40 3 +20 5 2 30 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 +20 5 nany +30 +30 5 with data § • c) 95% confidence bity within subt	$\begin{array}{c} 10/695\\ 26/1105\\ 2/59\\ 0/27\\ 6/392\\ 1/43\\ 0/110\\ 8/375\\ 0/15\\ -/6\\ 3/48\\ 0/0\\ \hline {\bf 56}/\\ 2875\\ (1-9\%/y)\\ 232/\\ 13671\\ (1.7\%/y)\\ ce intervals\\ cotals: \chi^2_2 = \\ cotals: \chi^2_2 = \\ cotals: \chi^2_2 = \\ 0 = \chi^2_2 = \\ 0 = \chi^2_2 = \chi$	6/562 17/966 3/50 0/40 7/506 0/48 1/98 8/389 0/4 -/7 4/108 0/2 46/ 2780 (1.7%/y) 224/ 12496 (1.8%/y) : 6.3; p = = 26.6; p	2:1 0:0 -0:6 (no 0:2 0:5 (no -0:2 0:3 (no (no 2:3 -10:5 0:04 > 0:1;	3.5 8.9 0.2 – data) 2.8 0.3 - data) 3.8 1.5 data) data) 20.9 92.6	0.5 1 Tamoxifen better	1.12 (SE 0.23 increase 2p > 0.1; NS 0.893 (SE 0.05 reduction 2p > 0.1; NS 0 1.5 2.0 Tamoxifen worse ct 2p > 0.1: NS

* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of events/woman-years.

p 33: RRs for death with recurrence, one line / trial, ER-unknown disease: by tam. duration



 * For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

p 34: RRs for death without recurrence, one line / trial, ER-unknown disease: by tam. duration



* For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/woman-years.



§ 1 trial with no data does not contribute to subtotals or to the overall total (allocated tamoxifen: 125; allocated control: 130) * For balance, control patients in 3-way trials or trial strata count half or twice in subtotal(s) and in final total of deaths/women.

Page 36: List of trials included in the EBCTCG meta-analysis of ~5 years of tamoxifen versus not: selected publications listed in chronological order of year starting

Year	Text	Trial name	Publication(s)
76G	22	Stockholm	Rutavist LE Johansson H. for the Stockholm Breast Cancer Study Group Long-term follow-up of the
100		Adjuvant Tamoxifen Trial	randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol 2007; 46 : 133–45.
78D	23,24	Scottish	Breast Cancer Trials Committee, Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of
			operable breast cancer: the Scottish trial. <i>Lancet</i> 1987; 2 : 171–5.
			Stewart HJ, Prescott RJ, Forrest APM. Scottish Adjuvant Tamoxiten Trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93 : 456–62.
78F	17	CRFB Caen C5	Delozier T, Julien JP, Juret P, et al. Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial. <i>Breast Cancer Res Treat</i> 1986; 7 : 105–09.
80H	18,19	Marseille	Ayme Y, Spitalier JM, Amalric R, et al. Preliminary results of a three-arm randomized trial of adjuvant
			chemo- and/or hormone-therapy for high-risk breast cancer. Fourth EORIC breast cancer working
			Spyratos F. et al. Re-evaluation of the indications of adjuvant hormonotherapy in high risk primary breast
			cancer patients. <i>Bull Cancer</i> 1991; 78 : 709–723.
82%	25,26	NSABP B-14	Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast
			Cancer patients with negative lymph nodes and estrogen receptor-positive tumors [see comments]. J Nati
			Fisher B. Dignam J. Bryant J. Wolmark N. Five versus more than five years of tamoxifen for lymph node-
			negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-
0.014			14 randomized trial. <i>J Natl Cancer Inst</i> 2001; 93 : 684–90.
82M	15		Personal communication Recearde F. Pubagetti A. Bruzzi P. et al. Chemotherapy versus tamovifen versus chemotherapy plus
000	15	GROCIAT	tamoxifen in node-positive, estrogen receptor-positive breast cancer patients; Results of a multicentric
			Italian study. <i>J Clin Oncol</i> 1990; 8: 1310–20.
89@	6	Bari, Italy	Paradiso A, De Lena M, Sambiasi M, et al. Adjuvant hormonotherapy for slow-proliferating node-negative breast cancer patients. Results of the phase III trial of NCI-Bari. <i>Breast</i> 2003; 12 : S40, P90.
89L	4	NSABP B-21	Fisher B, Bryant J, Dignam JJ, Wickerham DL, et al. Tamoxifen, radiation therapy, or both for prevention
			of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one
96M	16	CRER Coop 002	centimeter or less. J Clin Oncol 2002; 20: 4141-49.
00101	10	CRFB Caell 002	randomized trial. Fourth International Congress on Anti-cancer Chemotherapy 1993 p.58: February 2-5.
			1993; Paris, France.
86P	20	FASG GFEA 02	Namer M, Fargeot P, Roche H, et al. Improved disease-free survival with epirubicin-based
			chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-
			07 trials. Ann Oncol 2006; 17 : 65–73.
89B	7	SWOG 8897 /	Hutchins LF, Green SJ, Ravdin PM, et al. Randomized, controlled trial of cyclophosphamide,
		INT 0102	methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without
			<i>Clin Oncol</i> 2005: 23: 8313–21
89F	8	ECOG EST	Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with
		5188 / INT 0101	axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101
010	21	EORTC 10001	(E5188). J Clin Oncol 2005; 23: 5973–82. Moreles L. Cappov P. Dvozka, L. et al. Postoporativo adjuvant chamothorapy followed by adjuvant
910	21	EORIC 10901	tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European
			Organisation for Research and Treatment of Cancer Breast Group. Eur J Cancer 2007; 43: 331–40.
91H	9	NSABP B-23	Fisher B, Anderson S, Tan Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative,
			estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel
92N1	10	ICCG C/9/91 UK	Bliss JM, Wils J, Marty M et al. Evaluation of the tolerability of $FE_{50}C$ versus $FE_{75}C$ in a prospective
			randomised trial in adjuvant breast cancer patients. Proc Ann Meet Am Soc Clin Oncol 2002; 21: 51b,
005	-		
92P	5	BASUII	cancers of excellent prognosis: BASO II trial. <i>Eur J Cancer Suppl</i> 2008; 6 : 55, A17.
93B	11	NCIC MA.12	Bramwell VHC, Pritchard KI, Tu D, et al. A randomized placebo-controlled study of tamoxifen after
			adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada Clinical Trials Group Trial MA 12). App Opcol 2010: 21 : 283-90
93C	12	GABG-4-D-93	Kaufmann M. Graf E. Jonat W. et al. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy
			in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93) -
0.011	4.2		the German Adjuvant Breast Cancer Group. <i>J Clin Oncol</i> 2005; 23 : 7842–48.
93N	13	IBCSG 13-93	Ucileoni M, Gelber S, Goldhirsch A, et al. Lamoxiten atter adjuvant chemotherapy for premenopausal
			<i>Clin Oncol</i> 2006; 24 : 1332–41.
98X	14	GEPARDO	von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-
		Germany	stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable
1	1	1	carcinoma of the breast: a randomized, controlled, open phase lib study. J Clin Oncol 2001; 19: 3506–15.